Human papillomaviral load changes in low-grade squamous intraepithelial lesions of the uterine cervix

C-M Ho1,2,3, W-F Cheng4, T-Y Chu5, C-A Chen4, M-H Chuang6, S-F Chang*,3 and C-Y Hsieh4

1Gynecologic Cancer Center, Department of Obstetrics and Gynecology, Cathay General Hospital, Taipei, Taiwan, ROC; 2School of Medicine, Fu Jen Catholic University, Hsinchuang, Taipei, Hsien, Taiwan, ROC; 3Graduate Institute of Cell and Molecular Biology, Taipei Medical University, 250 Wu-Hsing Street, Taipei, Taiwan 110, ROC; 4Department of Obstetrics and Gynecology, National Taiwan University Hospital, National Taiwan University, Taipei, Taiwan, ROC; 5Department of Obstetrics and Gynecology, Buddhist Tzu Chi General Hospital, Hualien, Taiwan, ROC; 6Division of Biostatistics and Bioinformatics, National Health Research Institutes, Miaoli, Taiwan, ROC.

To better predict risk of progression of low-grade squamous intraepithelial lesions (LSILs) of the uterine cervix in women with human papillomavirus (HPV) infections, 294 baseline cervical specimens from women with LSILs were evaluated. Specimens were tested for HPV DNA using hybrid capture 2 (HC2) and PCR-reverse line blotting. 65 LSILs with HPV DNA types 16, 18, 52, or 58 were examined for physical status, E2/E6 ratio and viral load at two time points, along with patient age. Women with LSILs whose viral loads increased between baseline and 6 month follow-up had a 45% risk of developing HSIL (OR = 7.6, 95% CI = 1.9 – 29.4, P < 0.01), as evaluated by real-time PCR and a 44% risk (OR = 6.1, 95% CI = 1.6 – 22.7, P < 0.01), as evaluated by HC2. The two viral load measures correlated well (Person’s coefficient, r = 0.687, P < 0.001). Such evaluations of viral load changes (increased or not increased) through repeat HPV DNA testing could predict progression of disease in LSIL cases of HPV types 16, 18, 52, and 58, which correlates to clinical implications.

British Journal of Cancer (2006) 95, 1384–1389. doi:10.1038/sj.bjc.6603430 www.bjcancer.com
Published online 24 October 2006
© 2006 Cancer Research UK

Keywords: HPV; low-grade squamous intraepithelial lesions; viral load; integration; hybrid capture 2

Human papillomavirus (HPV) plays an important role in the carcinogenesis of cervical cancer (Bosch et al, 1995; Walboomers et al, 1999). The most common oncogenic HPV type in preinvasive and cervical cancer is HPV 16, detectable in 21% of women with low-grade squamous intraepithelial lesions (LSILs) (Castle et al, 2005), in more than 50% of women with cervical intraepithelial neoplasia grade 3 (CIN 3), and women with cervical cancer in America and Europe (Bosch et al, 1995; Herrero et al, 2000; Munoz et al, 2003). HPV 18 causes 10–15% of CIN 3 and cervical cancers (Bosch et al, 1995). In addition, HPV 18 also causes more than 35% of cervical adenocarcinomas, which are difficult to detect by current screening methods (Bosch et al, 1995). Additionally, HPV 52 and 58 are as prevalent as HPV 16 and 18 in patients with preinvasive and cervical cancer in Taiwan and Asian countries (Liaw et al, 1995; Huang et al, 1997; Ho et al, 2005, 2006).

Approximately 50% of atypical squamous cells of undetermined significance (ASCUS) and 80% of LSILs are infected by oncogenic types of HPV (ALTS group, 2000; Solomon et al, 2001). HPV DNA testing for patients with ASCUS provides useful information and allows referral of patients for immediate colposcopy to detect high-grade squamous intraepithelial lesions (HSILs) and cancer (Solomon et al, 2001). In contrast, oncogenic HPV DNA testing is not informative for triage of patients with LSILs because a high percentage of LSIL patients are HPV positive (ALTS group, 2000). Repeated low-grade squamous intraepithelial lesions and cervical cancers are difficult to detect by current screening methods. A repeat Pap smear in 3–6 months or direct biopsy under colposcopy is generally used in clinical practice. Development of alternative triage strategies for women with LSILs would be valuable in distinguishing women with LSILs that have high probabilities of progression to HSILs from women with LSILs that have spontaneously regressed.

As a result of the lack of sufficiently large prospective longitudinal follow-up studies and the different geographic distributions of HPV types, it has not been established how the risk of HSILs differs during transition by physical status of HPV 16, 18, 52, and 58 DNA (integrated versus episomal DNA) during longitudinal follow-up, viral loads (high vs low) and viral load change (increased vs not increased) between baseline and follow-up among women with LSILs. To examine this issue, we evaluated the 2-year cumulative risk for HSIL attributable to HPV 16, 18, 52, and 58. To examine this issue, we evaluated the 2-year cumulative risk for HSIL attributable to HPV 16, 18, 52, and 58, the most common oncogenic types in pre-invasive cervical lesions including LSILs and HSILs in Asia, and questioned whether the integration of HPV oncogenes into a host genome contributed to the risk of LSILs progressing to HSILs. In addition, we determined if E6 viral load and its change contributed to the risk of LSILs progressing to HSILs during the 6-month interval between baseline diagnosis of LSIL by Pap smear and the 6-month follow-up visit by repeat Pap smear.
SUBJECTS AND METHODS
The Taiwan Cooperative Oncology Group (TCOG), conducted a multicenter study – T1899, entitled, ‘Human Papillomavirus DNA in Squamous Intraepithelial Lesions and Longitudinal Follow-up of Its Clinical Significance in Low-grade Squamous Intraepithelial Lesions of Uterine Cervix’, under the supervision of the National Health Research Institute of Taiwan. A total of 1246 women with abnormal Pap smears, including those diagnosed with ASCUS or AGUS (n = 431), LSIL (n = 437), and HSIL (n = 373), from August 1999 to March 2004 were enrolled. The details of the study design and population have been published (Sun et al, 2005; Chen et al, 2006). Of the 1246 participants, 936 underwent cervical biopsies for histological examinations.

Women with LSIL (n = 437) had Pap smears, HPV testing, and colposcopic examinations every 3 months during the follow-up period. Participants were excluded from the study if they had no follow-up data (n = 60), baseline cancer on pathological examination (n = 1), fewer than four follow-up visits (n = 82), or no baseline HPV data (n = 2). Women with histologically confirmed HSIL were defined as having disease progression were treated and exited from the study. Women with LSIL with two consecutive normal Pap smears or coned-out HPV clearance during the follow-up period were defined as in remission and also exited. Women with LSIL not in remission or progression were defined as having persistent disease. HPV persistence was defined as HPV positivity for a given type tested on two consecutive occasions vs clearance.

A total of 294 women with LSIL, having at least four follow-up visits every 3 months, were tested for HPV DNA using both HC2 and PCR-reverse line bloting and were included in our longitudinal follow-up study (unpublished data). Among the 294 patients with LSIL, 187 specimens from 65 women with HPV 16 (n = 14), 18 (n = 8), 52 (n = 30), and 58 (n = 13) were collected at baseline and followed-up every 6 months until follow-up showed disease progression. Patients with LSIL from HPV types other than HPV 16, 18, 52, or 58 were excluded from our study due to diffuse distribution and relatively small sample sizes in each type. The specimens were further tested for viral load, E2/E6 ratio and viral load change using real-time PCR. Of the 187 specimens, 12 (6%) were mixed infections. Four samples lacking of follow-up HPV DNA were excluded from final analysis. In addition, 212 HSIL positive patients with HPV 16 (n = 92), 18 (n = 5), 52 (n = 57), or 58 (n = 58) infections were also obtained and tested for viral load, E2/E6 ratio, and physical status of HPV DNA using real-time PCR to compare with data from LSIL specimens. We also tested the specimens for viral load and viral load change by hybrid capture two and compared these results to those obtained by real-time PCR to predict disease progression.

HPV DNA testing-HC2 and PCR methods
HC2 (Digene Corporation, Silver Spring, MD, USA) was used to examine for HPV DNA in each specimen, including a mixture of probes for cervical cancer-associated HPV types: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68. The US Food and Drug Administration approved threshold of 1 pg of HPV DNA ml⁻¹ of test solution was the positive control. The viral loads were expressed as copies of HPV genomes/100 ng. For the PCR method, MY09-MY11-HMB01 L1 consensus primers were used in the amplification process, followed by a single hybridisation with a reverse line blot detection method (the prototype of Roche linear array HPV test, Roche Molecular Systems Inc., Pleasanton, CA, USA). The HPV genotyping strips contained 29 probe lines plus one reference line, detecting 27 individual HPV genotypes and two concentrations of the β-globin control probe. Two bovine serum albumin (BSA)-conjugated probes per HPV probe per HPV type, corresponding to each of two hypervariable regions within the MY09/MY11 ampiclon, were deposited in a single line for each of the following HPV types: 16, 18, 26, 31, 33, 35, 39, 42, 45, 51 – 59, 66, 68, MM4, MM7, MM8, and MM9.

Real-time PCR
DNA amplifications were carried out in a 96-well reaction plate format in an ABI Prism 5700 Sequence Detection System. Amplification and quantification of the E2 and E6 genes were performed simultaneously in separate reaction tubes. Both the HPV E2 and E6 PCR reactions were performed in triplicate. Multiple negative water blanks were included in every analysis. The reactions of real-time PCR are described elsewhere (Ho et al, 2006). The specificity was verified by a dissociation curve. Two standard curves were obtained by amplification of a serial dilution of cloned HPV-16 (from base 28 to base 3980) or HPV-18 (from base 45 to base 3995) DNA fragments or HPV-52 (from base 95 to base 3895) or HPV-58 (from base 45 to base 3994) DNA in pGEM T-Easy vector containing equivalent amounts of E2 and E6 genes from 10 to 10 000 000 copies ml⁻¹. The number of threshold cycles obtained from E2 PCR and from E6 PCR was equivalent in each run. Linear plots of the log of copy number vs the number of the threshold cycle were consistently obtained for both genes, and the correlation coefficient was between 0.995 and 1.00 in each run.

The technique was developed on the assumption that: (1) preferential disruption of E2 causes the absence of E2 gene sequences in the PCR product following integration, (2) copy numbers of both genes should be equal when viral DNA presents in episomal forms, and (3) E2 gene copy numbers are smaller than the for E6 in concomitant forms.

Concentrations of HPV DNA were expressed as copies of the HPV genome in 100 ng of cellular DNA. Ratios of E2–E6 of less than 1 indicated the presence of both integrated and episomal forms. The integrated E6 was calculated by subtracting the copy numbers of E2 (episomal). The ratio of E2 to integrated E6 represented the amount of the episomal form in relation to the integrated form.

Statistical analyses
The 2-year cumulative risks stratified by the change of viral load at the first two time points (viral load increased or not increased) for histologically confirmed HSIL attributable to HPV 16, 18, 52, or 58 were analysed via the Kaplan-Meier method. Logistic regression analysis was used to calculate the odds ratios (OR) and their 95% confidence intervals (CIs) for HSIL associated with change of HPV load (increased vs not increased), high viral load (≥ 10⁵ ≤ 10⁶), age (≥ 30 vs < 30 years) and repeat Pap smear (abnormal vs normal). The correlation between HPV loads determined by real-time PCR and HC2 was estimated using Pearson’s correlation. The differences in HPV integration status between LSIL and HSIL groups were analysed using Fisher’s exact test. All statistical analyses were performed using SAS 9.13.

RESULTS
Among the 294 women with LSIL, having at least four follow-up visits in 3 months, 76.9% were HPV DNA positive by PCR. The frequencies of the major, baseline HPV genotypes were: HPV 16 (4.8%), 18 (2.4%), 52 (10.9%), 58 (4.1%), 53 (8.5%), and 51 (6.8%). The prevalence of HPV 16, 18, 52, and 58 in HSIL were as follows: 31.7% (92/290) – type 16, followed by 20.0% (58/290) – type 58, 19.7% (57/290) – type 52, and 1.7% (5/290) – type 18.

Median E6 viral loads
For the 61 eligible women with LSILs, the clinical characteristics and median viral loads are shown in Table 1. The median viral
High viral loads were defined as those greater than $10^5$ copies per 100 ng of DNA, which is equivalent to about 15,000 cells. Whereas, the HPV 16, 18, 52, or 58 viral loads tested by real-time PCR varied from 2.4 to 100 ng of DNA. The HPV 16, 18, 52, or 58 viral loads among women with LSILs differed significantly ($P = 0.049$ for HPV 16 E6, $P = 0.032$ for HPV 52 E6). The median viral load of HPV types 18 and 58 among women with LSILs and HSILs did not differ significantly ($P = 0.049$ for type 18, $P = 0.184$ for type 58). The median viral load ranged from $1.3 \times 10^4$ to $3.7 \times 10^5$ copies per 100 ng of DNA. Therefore, high viral loads were defined as those greater than $10^7$ copies per 100 ng of DNA. The HPV 16, 18, 52, or 58 viral loads tested by real-time PCR varied from $2.4 \times 10^4$ to $7.6 \times 10^5$ copies per 100 ng of DNA, which is equivalent to about 15,000 cells. Women who had high viral loads ($>10^5$ copies) vs low viral loads ($<10^5$ copies) at baseline had marginally significant increased risk of disease progression ($P = 0.07$).

### Table 1

|                | HPV 16       | HPV 18       | HPV 52       | HPV 58       |
|----------------|--------------|--------------|--------------|--------------|
| Percentage of each type | 23.0% (14/61) | 13.1% (8/61) | 42.6% (26/61) | 21.3% (13/61) |
| Median age (range) | 35 (range: 24–58) | 31 (range: 23–51) | 41 (range: 24–65) | 36 (range: 20–52) |
| Range of viral load for LSIL | 0–735,527 | 0–5,029,143 | 0–3,843,486 | 0–2,754,113 |
| Median E6 load for LSIL | 31,916 | 26,599 | 35,620 | 37,366 |
| Range of viral load for HSIL | 0–34,386,322 | 0–41,748 | 0–13,596,437 | 0–14,243,132 |
| P-value (median E6 load between LSIL and HSIL) | 0.049 | 0.499 | 0.032 | 0.184 |

*HSILs = high-grade squamous intraepithelial lesions.*

**Figure 1** Kaplan–Meier estimates of cumulative incidence of high-grade squamous intraepithelial lesions (HSILs) among the 61 women with low-grade squamous intraepithelial lesions (LSILs), according to HPV types 16, 18, 52, and/or 58.

**Two-year cumulative risk with dynamic change of HPV**

Overall, 61 women after cytological examination with LSILs attributable to HPV 16, 18, 52, or 58 had a 2-year cumulative risk of developing HSILs of 21.5%, 29.3% (4/14) with HPV 16 (OR = 1.5, 95% CI = 0.4–5.8, $P = 0.34$), 12.5% (1/8) with HPV 18 (OR = 0.6, 95% CI = 0.1–5.3, $P = 0.23$), 26.9% (7/26) with HPV 52 (OR = 0.7, 95% CI = 0.2–2.6, $P = 0.34$), and 7.7% (1/13) with HPV 58 (OR = 0.3, 95% CI = 0.0–2.1, $P = 0.61$) (Figure 1).

Based on viral load changes detected using real-time PCR, women with LSILs who had viral loads increases for HPV 16, 18, 52, or 58 between baseline and a 6 month follow-up had a 2-year risk of developing HSIL of 45%, seven-fold greater than those without increases in viral loads (OR = 7.6, 95% CI = 1.9–24.3, $P < 0.01$) (Figure 2). Overall, women with LSILs and persistent HPV infections had a 2-year cumulative risk of developing HSILs of 25%, compared –11.5% for those with transient infections (OR = 2.5, 95% CI = 0.5–12.7, $P = 0.27$) (Figure 3). Women with LSILs due to HPV 16, 18, 52, or 58, who had increases in viral loads between baseline and 6 month follow-up had risk of persistent abnormal Pap smears 45-fold greater than those without increased viral loads (OR = 45.6, 95% CI = 6.4–326.0, $P < 0.001$).

Using logistic regression for modelling changes in viral load data, repeat abnormal Pap smears, and patient age at enrollment, women with LSILs who had viral loads increase between baseline and 6 month follow-up for HPV 16, 18, 52, or 58 had increased risk for HSILs, as tested by real-time PCR (OR = 8.3, 95% CI = 2.0–34, $P < 0.01$) or HC2 (OR = 5.6, 95% CI = 1.5–21.4, $P < 0.01$). In addition, women with LSILs, repeat abnormal Pap smears (OR = 2.1, 95% CI = 0.5–8.3, $P > 0.05$), and aged younger than 30 years (OR = 1.8, 95% CI = 0.3–11.7, $P > 0.05$) did not show an increase in risk of developing HSILs (Table 2).

**Comparison of HPV viral load by HC2 and real-time PCR**

Real-time PCR and HC2 correlated well for determining viral load change (increased or not increased) at baseline and 6-month follow-up to predict disease progression. Based on viral load change tested by HC2, women with LSILs due to HPV 16, 18, 52, or 58 who had viral load increase between baseline and 6 month follow-up had risk of developing HSILs of 44%, six-fold greater...
than those without increased viral loads (OR = 6.1, 95% CI = 1.6–22.7). This result is consistent with real-time PCR of 45%, sevenfold greater than those without increased viral loads by real-time PCR. The logarithm of HPV 16, 18, 52, or 58 viral loads estimated by real-time PCR were plotted as functions of the logarithm of HPV viral loads estimated by HC2. The two measurements for viral load correlated well (Pearson's correlation coefficient $r = 0.69$, $P < 0.001$).

**Physical status of HPV 16, 18, 52, and 58 DNA in women with LSILs and longitudinal follow-up**

The prevalence of both integrated and episomal (mixed type) infections for women with LSILs at baseline for HPV 16, 18, 52, and 58 were as follows: 7.1% (1/14) – type 16, 12.5% (1/8) – type 18, 7.7% (2/26) – type 52, and 0% (0/13) – type 58. No pure single type of viral integration was found in women with LSILs due to HPV 16, 18, 52, and 58 at baseline or during follow-up. Integrated and episomal HPV 16, 18, 52, or 58 DNA was detected in only 1 of 13 (7.7%) specimens in progression among women during transition from LSILs to HSILs. The prevalence of integration of HPV 16, 18, 52, or 58 DNA between women with LSILs and HSILs increased significantly ($P < 0.001$). A significant difference or trend in the physical status of HPV 52, 18, or 58 DNA was found between patients with LSILs and HSILs ($P = 0.067$ for type 18, and $P = 0.065$ for HPV 58). However, no significant difference in the physical status of HPV 16 DNA was found between patients with LSILs and HSILs ($P = 0.46$). When the comparison was confined to tissue proved HSIL cases, the prevalence of integration of HPV 16, 18, 52, or 58 DNA was still significantly increased ($P < 0.001$). A significant difference or trend in the physical status of HPV 52 or
Table 2 OR and 95% confidence intervals (95% CI) for 2-year cumulative HSIL diagnoses associated with HPV 16, 18, 52, and 58 status, viral load change, age, high viral load, and repeat Pap smear.

| Characteristic                        | OR (95% CI) | P-value |
|---------------------------------------|-------------|---------|
| HPV risk                              |             |         |
| HPV 16 (n = 14)                       | 1.5 (0.4–5.8) | 0.34    |
| HPV 18 (n = 8)                        | 0.6 (0.1–5.3) | 0.23    |
| HPV 52 (n = 26)                       | 0.7 (0.2–2.6) | 0.34    |
| HPV 58 (n = 13)                       | 0.0 (0.0–2.1) | 1.61    |
| Baseline viral load                   |             |         |
| HPV DNA > 10^2 for HPV DNA ≤ 10^5   | 0.8 (0.2–3.1) | 0.07    |
| Virus load change                     |             |         |
| Viral load increase between baseline and 6-month follow-up for HPV testing | | |
| Real-time PCR                         | 8.3 (2.0–34) | <0.01   |
| Hybrid capture 2                      | 5.6 (1.5–21.4) | <0.01   |
| HPV persistence                       |             |         |
| Persistent HPV/Transient              | 2.5 (0.5–12.7) | 0.27    |
| Age at enrollment ≥ 30 or < 30        | 1.8 (0.3–11.7) | 0.19    |
| Repeat Pap smear                      |             |         |
| Abnormal or normal                    | 2.1 (0.5–8.3) | 1.27    |

P-value < 0.05 represents statistical significance ($^*$).

Additionally, neither repeat abnormal Pap smear nor age older than 30 years increased the risk of HSIL. Thus, increased HPV 16, 18, 52, and 58 viral loads was the single most important risk factor for HSIL in our study population.

The increase of viral load detected by both HC2 and real-time PCR methods predicted disease progression to HSIL, with HPV 16, 18, 52, and 58 viral loads detection correlating well (only 6% of tested specimens had mixed HPV types) and similar to Pre´tet et al (2004). We used a real-time PCR method for E6 HPV 16, 18, 52, and 58 quantifications to determine whether the HC2 assay could be suitable as a quantitative viral load assay for clinical practice. Recent data suggests that HR-HPV load would help to identify women at high risk for progression to HSIL (Joseffson et al, 2000; Lorincz et al, 2002). However, due to multiple infections of mixed reactivity of nononcogenic HPV types, and variability of cellularity of cervical scrapings, HC2 assay of HR-HPV load has not been validated as a quantitative test.

Although, specimens with HPV 16, 18, 52, and 58 represent about 43% of all LSILs (Chen et al, 2006), they represented 73% of HSILs in our cohort study. As a result of the relatively small proportion of HPV 16 in women with LSILs in Taiwan, it seems that distinguishing the risk of cervical precancer among HPV 16-positive women from the lower risk posed by other oncogenic HPV types might have limited clinical value. Alternatively, repeat HPV DNA testing 6 months after baseline testing to determine changes in viral load (increased or not increased) could predict progression of disease among women with LSILs due to HPV types 16, 18, 52, and 58, and might be clinically practical and valuable. Although it is useful for ASCUS triage (Solomon et al, 2001), HC2 is not recommended for LSIL triage because the high proportion of positive results makes it uninformative (ALTS group, 2000). Nonetheless, if the elevated risk of HSILs in patients who are positive for HPV 16, 18, 52, or 58 and have viral load increases over the first two time points at 6-month interval (33% of patients who are positive for HPV 16, 18, 52, or 58) warrants more aggressive treatment, then determination of viral load change (increase) of individual HPV 16, 18, 52, and 58 types might be useful for the management of women with LSILs. It is noteworthy that women who had undetectable HPV or viral loads at 1 log decreased between baseline and 6 months of follow-up still had 6% (234) risk of developing HSILs (data not shown). These data highlight that no single test or combination of tests will provide perfect negative reassurance of cervical precancer or cancer.

Several authors also note that the quantitative measurement of HPV DNA, as an evolutionary predictor or determinant of disease severity, is of greater value than a single HPV positive result. For example, the amount of HR HPV DNA increases the grade of the lesion. This increase was noted for HPV 16, but not for HPV 18, 31, 45, and 56 (Moberg et al, 2004). Moreover, the highest HPV 16 loads are predictive of the appearance of carcinoma in situ before any intraepithelial lesions are detectable (Joseffson et al, 2000). In a model of the temporal relationship in HPV-induced carcinoma, Peitsaro et al (2002) proposed that the probability of HPV DNA integration increases with high HPV 16 DNA load. In our study, the median viral loads of HPV type 16 and 52 in women with cytologies between LSIL and HSIL differed significantly, in contrast to those of HPV types 18 and 58. In our study, we could not compare the viral loads between women with integration in LSILs and women with episomal in LSILs, because of the low integration rate in LSILs cases. However, we compared the median viral loads of E6 between women with integration in primary HSILs and women with episomal in primary HSILs. There were no significant differences in pooling data (including HPV 16, 18, 52, or 58) or different type between these two groups of patients (data not shown).

The value of 1 pg of HPV genome ml⁻¹, which represents the HC2 assay threshold, corresponds to 10⁷ copies of HPV genome ml⁻¹. As the cervical samples harboured a mean of
5 \times 10^5 \text{ cells ml}^{-1}$, the HC2 cutoff represents $10^5$ HPV/5 $\times 10^5$ cells. Van Duin et al (2002) proposed that it was $2.4 \times 10^4$ HPV 16/ scrape (one scrape contains approximated $0.6 \times 10^5$ 2.2 $\times 10^5$ cells) for women with normal cytologies and $4.3 \times 10^6$ HPV 16/ scrape for women with abnormal cytologies. The real-time PCR and HC2 measurements of viral load correlated well, even without cell normalization in our study (Pearson’s correlation coefficient $r = 0.69$, $P < 0.001$). Load changes determined by HC2 also precisely predicted histological progression of LSILs to HSILs.

In order to elucidate the causal relationship of integration in LSIL progression to HSILs using real-time PCR method, we analysed HPV 16, 18, 52, and 58 DNA samples in 178 cervical swabs from women with LSILs and longitudinally monitored them every 3 months in a multicentre trial. We detected the integrated form only in 9/178 (5%) samples with the episomal form. Additionally, no pure integration was found in women with LSILs due to HPV 16, 18, 52, and 58 at baseline and during follow-up. Furthermore, integration (both integrated DNA and episomal DNA) of HPV 16, 18, 52, or 58 DNA was detected in only 1 of 13 (7.7%) specimens of women during transition from LSILs to HSILs. Although some studies (KulmA et al, 2006) reported that early integration is noted in women with LSILs, our data suggests that integration is not often detected in women with LSILs, and probably is not essential for progression during transition from LSILs to HSILs. On the other hand, the prevalence of integration of HPV 16, 18, 52, or 58 DNA among women progressing from LSILs to HSILs is significantly increased ($P < 0.001$), which is comparable with previous studies showing that integration is often detected in HSILs (Peitarsa et al, 2002). Although, there was no difference for HPV 16 infection between women with LSILs and HSILs, this may be due to small sample size or reasons not yet known. The possible role of HPV DNA integration may be a late event in carcinogenesis, especially when it occurs in HSILs or cervical cancer, or when LSIL skips directly to HSIL after persistent HPV infection.

In conclusion, we recommend that patients with LSIL, HPV types 16, 18, 52, or 58, consider detecting the viral load with real-time PCR or HC2 at the first visit and 6 months subsequently. Those with elevated viral loads are at risk of disease progression and should be carefully evaluated by colposcopy.

ACKNOWLEDGEMENTS

This research was supported by the Research Fund (MR9310) of Cathay General Hospital, Taipei, Taiwan, ROC.

REFERENCES

Bosch FX, Manos MM, Muñoz N, Sherman M, Jansen AM, Motoj PE, Schifman MH, Moreno V, Kurman R, Shah KV (1995) Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSSC) Study Group. Int J Natl Cancer Inst 87: 796 – 802.

Castle PE, Solomon D, Schifman M, Wheeler CM, for the ALTS Group (2005) Human papillomavirus type 16 infections and 2-year absolute risk of cervical precancer in women with equivocal or mild cytologic abnormalities. Int J Natl Cancer Inst 97: 1066 – 1071.

Chen CA, Liu CY, Chu HH, Chou CY, Ho CM, Twu NF, Kan YH, Chuang MH, Chu TY, Hsieh CY (2006) The distribution and differential risks of high-grade squamous intraepithelial lesions: a Taiwan Cooperative Oncologic Group (TCOG) Study. Int J Gynecol Cancer 16: 1081 – 1088.

Herrero R, Hildesheim A, Bratti C, Sherman ME, Hutchinson M, Morales J, Balmaceda I, Greenberg MD, Alfaro M, Burk RD, Wacholder S, Plummer M, Schifman M, (2000) Population-based study of human papillomavirus infection and cervical neoplasia in rural Costa Rica. J Natl Natl Cancer Inst 92: 464 – 474.

Ho CM, Chien TY, Huang SH, Lee BH, Chang SF (2006) Integrated human papillomavirus type 52 and 58 is infrequently found in cervical cancer and high viral loads predict risk of cervical cancer. Gynecol Oncol 102: 54 – 60.

Ho CM, Yang SS, Chien TY, Huang SH, Jeng CJ, Chang SF (2005) Detection and quantitation of human papillomavirus type 16, 18 and 52 DNA in the peripheral blood of cervical cancer patients. Gynecol Oncol 99: 615 – 621.

Huang S, Afonina I, Miller BA, Bechmann M (1997) Human papillomavirus types 52 and 58 are prevalent in cervical cancers from Chinese Women. J Natl Cancer Inst 89: 12 – 19.

Josephson AM, Magnusson PKE, Ylitalo N, Sorensen P, Owarforth-Tubbin P, Kulmala S-MA, Svrjanen SM, Gyllenstein UB, Shabalova IP, Petrovichev N, Liaw KL, Hsing AW, Chen CJ, Schiffman MH, Zhang TY, Husieh CY, Greer CE, You SL, Huang TW, Wu TC (1995) Human papillomavirus and cervical neoplasia: a case-control study in Taiwan. Int J Cancer 62: 565 – 571.

Lorincz AT, Castle PE, Sherman ME, Scott DR, Glass AG, Wacholder S, Rush BB, Gravitt PE, Schussler JE, Schifman M (2002) Viral load of human papillomavirus and risk of CIN3 or cervical cancer. Lancet 360: 228 – 229.

Moberg M, Gustavsson I, Gyllensten Ulf (2004) Type-specific associations of human papillomavirus load with risk of developing cervical carcinoma in situ. Int J Cancer 112: 854 – 859.

Munoz N, Bosch FX, de San Jose S, Herrero R, Castellsague X, Shah KV, Snijders PFJ, Meijer CJLM, for the International Agency for Research on Cancer Multicenter Cervical Cancer Study Group (2003) Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 348: 518 – 527.

Peitarsa P, Johannson B, Syrjanen S (2002) Integrated human papillomavirus type 16 is frequently found in cervical cancer precursors as demonstrated by a novel quantitative real-time PCR technique. J Clin Microbiol 40: 886 – 891.

Pre‡et JL, Dalstein V, Monnier-Benoit S, Delpeut S, Mougin C (2004) High risk HPV load estimated by Hybrid Capture II correlates with HPV16 load measured by real-time PCR in cervical smears of HPV16-infected women. J Clin Virol 31: 140 – 147.

Solomon D, Schifman M, Tarone R (2001) Comparison of three management strategies for patients with atypical squamous cells of undetermined significance: baseline results from a randomized trial. J Natl Cancer Inst 93: 293 – 299.

Sun CA, Hsiung CA, Lai CH, Chen CA, Chou CY, Ho CM, Twu NF, Feng WL, Chuang MH, Hsieh CY, Chu TY (2005) Epidemiologic correlates of cervical human papillomavirus prevalence in women with abnormal pap smear tests: a Taiwan Cooperative Oncology Group (TCOG) Study. J Med Virol 77: 273 – 281.

The Atypical Squamous Cells of Undetermined Significance/Low-Grade Squamous Intraepithelial Lesions Triage Study (ALTS) Group (2000) Human papillomavirus testing for triage of women with cytologic evidence of low-grade squamous intraepithelial lesions: baseline data from a randomized trial. J Natl Cancer Inst 92: 397 – 402.

van Duin M, Snijders PJ, Schrijnemakers HF, Voorhorst FJ, Rozenauda L, Nobbenhuis MA, van den Brule AJC, Verheijen RHM, Helmerhorst TJ, Meijer CJLM (2004) Type-specific associations of human papillomavirus integration with risk of developing cervical carcinoma. Int J Cancer 112: 854 – 859.

Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Peto J, Meijer CJLM, Munoz N (1999) Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189: 12 – 19.

Low-grade squamous intraepithelial lesions

C-M Ho et al

Molecular Diagnostics